Reverse transcription recombinase-aided amplification assay for rapid detection of the influenza A(H1N1)pdm09 H275Y mutation that confers oseltamivir resistance

Mol Cell Probes. 2021 Dec:60:101771. doi: 10.1016/j.mcp.2021.101771. Epub 2021 Sep 21.

Abstract

The emergence of the influenza A(H1N1)pdm09 virus with the NA-H275Y mutation, which confers oseltamivir resistance, must be monitored, especially in patients undergoing neuraminidase inhibitor treatment. In this study, we developed a reverse transcription recombinase-aided amplification assay that has high sensitivity (detection limit: 1.0 × 101 copies/μL) and specificity for detecting the oseltamivir-resistant H275Y mutation; the assay is performed within 30 min at a constant temperature of 39° Celsius using an isothermal device. This method is suitable for the clinical application of targeted testing, thereby providing technical support for precision medicine in individual drug applications for patients with severe infection or immunosuppression.

Keywords: A(H1N1)pdm09; Influenza virus; Resistance mutation; Reverse-transcription recombinase-aided amplification.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Resistance, Viral / genetics
  • Humans
  • Influenza A Virus, H1N1 Subtype* / genetics
  • Influenza, Human* / diagnosis
  • Influenza, Human* / drug therapy
  • Mutation
  • Mutation, Missense
  • Neuraminidase / genetics
  • Oseltamivir / pharmacology
  • Recombinases
  • Reverse Transcription

Substances

  • Recombinases
  • Oseltamivir
  • Neuraminidase